公司概述
Sol-Gel Technologies Ltd. operates within the healthcare sector, specifically focusing on the biotechnology industry, where it develops topical dermatological drugs for patients suffering from severe skin conditions across markets including Israel, China, Switzerland, Canada, the United States, and internationally. The company's primary product offering includes Twyneo, which is characterized as a once-daily, non-antibiotic topical formulation designed to treat these specific dermatological needs. In terms of scale, the company holds a market capitalization of $241.77 million while maintaining an annual revenue of $19.39 million over the trailing twelve-month period. These financial figures, combined with an employee count of 28, indicate that Sol-Gel Technologies Ltd. functions as a small-cap entity with a revenue base that is currently significantly lower than its market valuation, suggesting a high market premium relative to its current operational output.
财务健康
The company reported a revenue of $19.39 million for the trailing twelve months, yet this generated a net income of -$6,127,000 and an EBITDA of -$7,483,000, revealing a cost structure where operating expenses and non-operating costs substantially exceed gross profits. Despite the negative net income, the company recorded a free cash flow of $617,000, which provides a degree of financial flexibility by generating cash from operations even while reporting accounting losses. The margin profile is particularly constrained, with a gross margin of -17.6%, an operating margin of -497.8%, and a profit margin of -31.6%, indicating that the company is unable to cover its variable or fixed costs with its current sales revenue. On the balance sheet, Sol-Gel Technologies Ltd. holds $24.00 million in cash against $991,000 in debt, supported by a debt-to-equity ratio of 4.34, which suggests a highly leveraged capital structure despite the cash reserves. The current ratio stands at 4.37, indicating that the company possesses liquid assets more than four times its current liabilities, which points to robust short-term liquidity positioning. However, the return on equity is -23.7% and the return on assets is -14.4%, metrics that reveal management has not yet achieved positive returns on the capital invested or the assets owned.
估值评估
Valuation metrics for Sol-Gel Technologies Ltd. present a complex picture, with a P/E Ratio (TTM) listed as N/A due to the lack of positive earnings and a Forward P/E of -10.94, implying that the market anticipates continued negative earnings in the near future. The price-to-book ratio is 9.10, which indicates that the stock trades at a significant premium over its book value, suggesting investor expectations for future growth that have not yet been realized in the financial statements. Alternative valuation measures further highlight this divergence, with a price-to-sales ratio of 12.47 and an EV/EBITDA of -24.90, suggesting the market is pricing the stock based on future potential rather than current profitability. The stock has exhibited significant volatility, trading between a 52-week high of $97.97 and a 52-week low of $4.02, with the current price situated well below the recent peak. The beta value is 1.27, which means the stock's price volatility is higher than the broader market, reflecting the inherent risks associated with early-stage biotechnology development.
Growth & Income
Sol-Gel Technologies Ltd. has demonstrated aggressive expansion with a revenue growth year-over-year of 150.4%, whereas earnings growth is listed as N/A due to the company's ongoing losses, implying that revenue expansion is occurring without corresponding profitability improvement. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available earnings are theoretically reinvested into the business or used to reduce losses rather than distributed to shareholders. This growth and income profile is typical of biotechnology firms in the development phase, where capital is prioritized for research and product development rather than shareholder returns. The overall financial trajectory shows a company prioritizing rapid revenue scaling in the dermatological drug market while managing significant operational deficits and high valuation multiples.